A5007341838- Venous Thromboembolism Diagnosis and Management
- Blood Coagulation and Thrombosis Mechanisms
- Atrial Fibrillation Management and Outcomes
- Myeloproliferative Neoplasms: Diagnosis and Treatment
- Central Venous Catheters and Hemodialysis
- Brain Metastases and Treatment
- Intracerebral and Subarachnoid Hemorrhage Research
- Platelet Disorders and Treatments
- Antiplatelet Therapy and Cardiovascular Diseases
- Eosinophilic Disorders and Syndromes
- Acute Ischemic Stroke Management
- Acute Myocardial Infarction Research
- Extracellular vesicles in disease
- Cancer Treatment and Pharmacology
- Chronic Myeloid Leukemia Treatments
- Blood properties and coagulation
- Heparin-Induced Thrombocytopenia and Thrombosis
- Coagulation, Bradykinin, Polyphosphates, and Angioedema
- Immunotherapy and Immune Responses
- Cardiac tumors and thrombi
- Inflammatory Biomarkers in Disease Prognosis
- Lymphoma Diagnosis and Treatment
- Endoplasmic Reticulum Stress and Disease
- COVID-19 and healthcare impacts
- Systemic Sclerosis and Related Diseases
Memorial Sloan Kettering Cancer Center
2022-2025
Cornell University
2023-2024
Kettering University
2023-2024
Beth Israel Deaconess Medical Center
2014-2023
Harvard University
2013-2023
Hadassah Medical Center
2015-2023
Amsterdam University Medical Centers
2023
Harvard University Press
2020
Thrombosis Research Institute
2015-2019
Massachusetts General Hospital
2019
Low-molecular-weight heparin is the standard treatment for cancer-associated venous thromboembolism. The role of with direct oral anticoagulant agents unclear.
Abstract Purpose: Despite the strong association between malignant disease and thromboembolic disorders, molecular cellular basis of this relationship remains uncertain. We evaluated hypothesis that tumor-derived tissue factorbearing microparticles in plasma contribute to cancer-associated thrombosis. Experimental Design: developed impedance-based flow cytometry detect, quantitate, size platelet-poor plasma. number a cohort cancer patients different histologies (N = 96) conducted...
In terrestrial mammals, the oxygen storage capacity of CNS is limited, and neuronal function rapidly impaired if supply interrupted even for a short period time. However, tension monitored by peripheral (arterial) chemoreceptors not sensitive to regional differences in partial pressure (P<sub>O<sub>2</sub></sub>) that reflect variable levels activity or local tissue hypoxia, pointing necessity functional brain sensor. This experimental animal (rats mice) study shows astrocytes, most numerous...
In the Hokusai VTE Cancer study, edoxaban was non-inferior to dalteparin for composite outcome of recurrent venous thromboembolism (VTE) and major bleeding in 1,050 patients with cancer-associated VTE. The absolute rate 3.4% lower edoxaban, whereas 2.9% higher. present analysis focuses on sites, clinical presentation, course events, associated tumour types. Major bleeds their severity (categories 1–4) were blindly adjudicated by a committee using priori defined criteria, data analysed safety...
A personalized DC/AML fusion cell vaccine promotes the expansion of leukemia-specific T cells and prolonged remission in patients.
Protein disulfide isomerase (PDI) is a thiol secreted by vascular cells that required for thrombus formation. Quercetin flavonoids inhibit PDI activity and block platelet accumulation fibrin generation at the site of injury in mouse models, but clinical effect targeting extracellular humans has not been studied.We conducted multicenter phase II trial sequential dosing cohorts to evaluate efficacy with isoquercetin reduce hypercoagulability cancer patients high risk thrombosis. Patients...
Summary Elevated levels of circulating tissue factor‐bearing microparticles ( TFMP ) have been associated with an increased risk developing venous thromboembolism VTE in cancer patients. We performed a randomized phase II study to evaluate the cumulative incidence advanced patients lower not receiving thromboprophylaxis and those higher enoxaparin or observation. The at 2 months group N = 23) was 5·6% while observation arm 11) 27·3% (Gray test P 0·06). low 7·2% 32). No major haemorrhages...
BACKGROUND: Protein disulfide isomerase (PDI) is required for thrombus formation. We previously demonstrated that glycosylated quercetin flavonoids such as isoquercetin inhibit PDI activity and formation in animal models, but whether extracellular represents a viable anticoagulant target humans how its inhibition affects blood coagulation remain unknown. METHODS: evaluated effects of oral administration on platelet-dependent thrombin generation healthy subjects patients with persistently...
Importance The optimal pharmacologic thromboprophylaxis agent after total hip and knee arthroplasty is uncertain consensus lacking. Quantifying the risk of postoperative venous thromboembolism (VTE) bleeding evaluating comparative effectiveness safety strategies can inform care. Objective To quantify factors for VTE compare patient outcomes among pharmacological agents used arthroplasty. Design, Setting, Participants This retrospective cohort study data from a large health care claims...